EVOFEM BIOSCIENC(US:EVFM)2025-11-13 21:19Financial Performance - Net sales increased by 10% to $5.0 million in Q3 2025, compared to $4.5 million in the prior year quarter[4] - Operating income of $1.0 million was reported for Q3 2025, a significant improvement from a loss of $2.4 million in the same quarter last year[8] - Total operating expenses decreased by 42% to $4.0 million in Q3 2025, down from $6.9 million in the prior year quarter[7] - The net loss attributable to common stockholders was $1.7 million in Q3 2025, compared to a net loss of $2.4 million in Q3 2024, equating to a loss of $0.01 per share[9] - Restricted cash increased to $0.8 million as of September 30, 2025, compared to $0.7 million as of December 31, 2024[10] - The company reported a total stockholders' deficit of $75.1 million as of September 30, 2025[16] Cost Management - The company achieved a reduction in manufacturing costs by approximately 50% for both PHEXX and SOLOSEC, enhancing per-unit profit and facilitating entry into price-sensitive global markets[4] Regulatory and Clinical Developments - SOLOSEC was submitted for marketing approval in the UAE in Q3 2025 under a License and Supply Agreement with Pharma 1[4] - The company is conducting a Phase 4 clinical trial for SOLOSEC, hypothesizing a 1.75 lower rate of repeat infections compared to metronidazole[4] Corporate Actions - Evofem terminated the merger agreement with Aditxt following stockholder disapproval on October 20, 2025[5]